| Literature DB >> 27733193 |
Valery S Effoe1,2, Jeffrey A Katula3, Julienne K Kirk4, Carolyn F Pedley5, Linda Y Bollhalter6, W Mark Brown7, Margaret R Savoca6, Stedman T Jones6, Janet Baek8, Alain G Bertoni6,9.
Abstract
BACKGROUND: The use of the electronic medical record (EMR) system in recruitment in clinical trials has the potential for providing a very reliable and cost-effective recruiting methodology which may improve participant recruitment in clinical trials. We examined a recruitment approach centered on the use of the EMR, as well as other traditional methods, in the Lifestyle Intervention for Treatment of Diabetes (LIFT Diabetes) trial.Entities:
Keywords: African Americans; Community-based interventions; Electronic medical records; Lifestyle interventions; Randomized controlled trial; Recruitment methods; Type 2 diabetes
Mesh:
Year: 2016 PMID: 27733193 PMCID: PMC5062894 DOI: 10.1186/s13063-016-1631-7
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 2Cumulative number of participants randomized versus the study goal in the LIFT Diabetes trial (period from June 2013 to March 2015). The solid line represents the study goal, while the dashed line is a plot of the actual number randomized for the study
Fig. 1Flowchart of the recruitment process for the LIFT Diabetes trial. Community screenings refers to screenings during health and church fairs. Media refers to television, radio, and print advertisements. Referrals were from healthcare providers, study staff, participants’ friends and relatives, and other studies. Unknown/other refers to participants whose source of recruitment was either unknown or from the Wake Forest Be Involved website, ClinicalTrials.gov website, and other online advertisement. DSM diabetes self-management, LWL lifestyle weight loss
Demographic and clinical characteristics of LIFT Diabetes participants by enrollment status
| Characteristic | Total screened participants | Non-enrolled participants | Enrolled participants |
|
|---|---|---|---|---|
| Phone screen eligible, | 1102 | 842 | 260 | |
| Age, years | 55.0 ± 11.6 | 54.7 ± 11.8 | 56.3 ± 10.7 | 0.054 |
| Female, | 674 (62.9) | 502 (61.8) | 172 (66.2) | 0.21 |
| Race/ethnicity | 0.012 | |||
| Non-Hispanic black | 584 (55.0) | 459 (57.3) | 125 (48.1) | |
| Non-Hispanic white | 391 (36.9) | 273 (34.1) | 118 (45.4) | |
| Hispanic | 31 (2.9) | 25 (3.1) | 6 (2.3) | |
| Other (NA, AN, AI, Asian, PI) | 55 (5.2) | 44 (5.5) | 11 (4.2) | |
| Screening visit eligible, | 407 | 147 | 260 | |
| Age, years | 55.3 ± 10.7 | 53.7 ± 10.3 | 56.3 ± 10.7 | 0.033 |
| Female, | 264 (64.9) | 92 (62.6) | 172 (66.2) | 0.47 |
| Race/ethnicity | 0.054 | |||
| Non-Hispanic black | 206 (50.6) | 81 (55.1) | 125 (48.1) | |
| Non-Hispanic white | 168 (41.3) | 50 (34.0) | 118 (45.4) | |
| Hispanic | 15 (3.7) | 9 (6.1) | 6 (2.3) | |
| Other (NA, AN, AI, Asian, PI) | 18 (4.4) | 7 (4.8) | 11 (4.2) | |
| Smoking status, | 0.44 | |||
| Current | 67 (16.8) | 27 (19.4) | 40 (15.4) | |
| Former | 125 (31.3) | 39 (28.1) | 86 (33.1) | |
| Never | 207 (51.9) | 73 (52.5) | 134 (51.5) | |
| Body mass index, kg/m2 | 38.1 ± 8.8 | 38.7 ± 9.3 | 37.8 ± 8.5 | 0.33 |
| Body mass index categories, kg/m2 | 0.65 | |||
| 25–29.9 | 74 (18.3) | 24 (16.7) | 50 (19.2) | |
| 30–34.9 | 125 (30.9) | 41 (28.5) | 84 (32.3) | |
| 35–39.9 | 88 (21.8) | 35 (24.3) | 53 (20.4) | |
| ≥ 40 | 117 (29.0) | 44 (30.6) | 73 (28.1) | |
| Diabetes medication use, | 325 (79.9) | 100 (68.0) | 225 (86.5) | <0.0001 |
| Hypertension medication use, | 303 (74.5) | 94 (63.9) | 209 (80.4) | <0.001 |
| Lipid-lowering medication use, | 208 (51.1) | 60 (40.8) | 148 (56.9) | 0.002 |
| HbA1c | 7.8 ± 1.7 | 8.1 ± 2.1 | 7.6 ± 1.3 | 0.57 |
| Duration of diabetes, years | 8.6 ± 8.0 | 8.8 ± 8.5 | 8.5 ± 7.8 | 0.99 |
| Estimated GFR, ml/min/1.73 m2 | 92.4 ± 22.2 | 93 ± 22 | 92.1 ± 22.3 | 0.23 |
| Systolic blood pressure, mmHg | 127.1 ± 16.7 | 128.6 ± 18.4 | 126.3 ± 15.7 | 0.37 |
| Diastolic blood pressure, mmHg | 77.0 ± 10.4 | 78.8 ± 10.3 | 76.1 ± 10.3 | 0.046 |
| Triglycerides, mg/dl | 169.8 ± 106.0 | 172.3 ± 114.2 | 168.5 ± 101.7 | 0.88 |
Data are mean ± SD or number (percentage)
AI American Indian, AN Alaskan native, GFR glomerular filtration rate, NA Native American, PI Pacific Islander
Exclusion criteria by race/ethnic group at the time of the prescreen and clinic screening visit in the LIFT Diabetes trial
| Total screened ( | African Americans ( | Other race/ethnic groups ( |
| |
|---|---|---|---|---|
| Non-diabetic | 15 (1.9 %) | 5 (1.1 %) | 10 (2.9 %) | 0.07 |
| Under 25 and always on insulin | 7 (0.9 %) | 7 (1.5 %) | 0 (0 %) | 0.02 |
| BMI <25 kg/m2 or <27 kg/m2 for insulin users | 71 (8.9 %) | 42 (9.2 %) | 29 (8.5 %) | 0.80 |
| History of CVD or cardiovascular procedure* | 132 (16.5 %) | 70 (15.3 %) | 62 (18.1 %) | 0.29 |
| Alcohol (>14 drinks for men aged 65 years or less, > 7 drinks for men and women aged over 65 years) or drug abuse | 11 (1.4 %) | 2 (0.4 %) | 9 (2.6 %) | 0.01 |
| Other medical conditions (including chronic disease, leg amputation, blood clot, IBD, Crohn’s disease, acromegaly) | 43 (5.4 %) | 31 (6.8 %) | 12 (3.5 %) | 0.06 |
| Prior weight loss surgery | 19 (2.4 %) | 12 (2.6 %) | 7 (2 %) | 0.65 |
| History of cancer | 4 (0.5 %) | 2 (0.4 %) | 2 (0.6 %) | 1.00 |
| Unable to exercise | 43 (5.4 %) | 29 (6.3 %) | 14 (4.1 %) | 0.21 |
| Use of steroid pills or shots | 33 (4.1 %) | 18 (3.9 %) | 15 (4.4 %) | 0.86 |
| Unwilling to stop weight loss medications/program | 13 (1.6 %) | 6 (1.3 %) | 7 (2 %) | 0.42 |
| Pregnancy, breastfeeding | 6 (0.7 %) | 5 (1.1 %) | 1 (0.3 %) | 0.25 |
| Hospitalized depression/PHQ-9 | 11 (1.4 %) | 3 (0.7 %) | 8 (2.3 %) | 0.06 |
| Physician review includes PAR-Q | 53 (6.6 %) | 31 (6.8 %) | 22 (6.4 %) | 0.89 |
| Blood pressure ≥160/100 mmHg | 8 (1.0 %) | 5 (1.1 %) | 3 (0.9 %) | 1.00 |
| HbA1c ≥11 % | 42 (5.2 %) | 25 (5.4 %) | 17 (5 %) | 0.87 |
| Laboratory exclusions (GFR <45, triglycerides >600) | 10 (1.2 %) | 3 (0.7 %) | 7 (2 %) | 0.11 |
| Other reasons (household member works for LIFT, cannot commit to travel, another research study, schedule conflict, no PCP, needs sign language interpreter, ineligible with no reason given) | 109 (13.6 %) | 59 (12.9 %) | 50 (14.6 %) | 0.47 |
| Decided not to participate/no show | 171 (21.3 %) | 104 (22.7 %) | 67 (19.6 %) | 0.34 |
*Includes: MI, stroke, TIA, coronary bypass surgery, coronary angioplasty, heart balloon surgery, stenting, and cardiac rehabilitation
BMI body mass index, CVD cardiovascular disease, GFR glomerular filtration rate, HbA1c glycosylated hemoglobin, IBD inflammatory bowel disease, MI myocardial infarction, PAR-Q physical activity readiness questionnaire, PCP primary care physician, PHQ-9 patient health questionnaire, TIA transient ischemic attack
Fig. 3a Recruitment percent yield. b Percentage of participants enrolled. Data are presented by recruitment method. The horizontal axis displays the different recruitment methods. The numbers on the bars indicate the actual number of participants enrolled for each method. Community screening refers to screenings during health and church fairs. Media refers to television, radio, and print advertisements. Referrals were from healthcare providers, study staff, participants’ friends and relatives, and other studies. Unknown/other refers to participants whose source of recruitment was either unknown or from the Wake Forest Be Involved website, ClinicalTrials.gov website, and other online advertisement. AA African American, EMR electronic medical record